Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492
Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492
复制标题
DOI：
10.1200/jco.2000.18.5.972
复制
发表时间：
2000-03-01
影响因子：
45.3
通讯作者：
Cassileth, P
中科院分区：
文献类型：
--
作者：
Horning, SJ;Wiliams, J;Cassileth, P
目的：本研究在多机构环境下进行，以评估Stanford V化疗方案加放疗对大面积霍奇金病部位的疗效和可行性。患者和方法：在一项II期研究中实施了两阶段设计战，涉及47例大面积纵隔I/II期或III/IV期霍奇金病患者。12周的Stanford V化疗方案给予大于或等于5cm的淋巴结和/或宏观脾疾病的巩固放疗（36 Gy），治疗方法在参与东部肿瘤合作组的五个机构之一进行。结果：中位随访4.8年，45例患者存活，40例患者持续无病。估计2年和5年的进展自由度分别为87%和85%。2年和5年的总生存率为96%，有1例死于霍奇金病，1例死于M5急性白血病。7例复发患者中有6例接受了高剂量治疗和自体干细胞移植，3年时7例复发患者的第二次进展自由度估计为98%。在多机构环境下，Stanford V化疗和巩固放疗对大体积和晚期霍奇金病是有效的。在此基础上，开展了一项比较多柔比星、博来霉素、长春碱和达卡巴嗪与Stanford V方案的组间研究。[J]中华肿瘤杂志，2000,18(3):344 - 344。
Purpose: This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites,Patients and Methods: A two-stage design war implemented in a phase II study involving 47 patients with bulky mediastinal stage I/II or stage III/IV Hodgkin's disease. Twelve weeks of the Stanford V chemotherapy regimen were given with consolidative radiotherapy (36 Gy) to lymph nodes greater than or equal to 5 cm and/or macroscopic splenic disease, Treatment wets administered in one of five institutions participating in the Eastern Cooperative Oncology Group.Results: With a median follow-up of 4.8 years, 45 patients are alive and 40 have been continuously disease-free. The estimated freedom from progression was 87% at 2 years and 85% at 5 years. Overall survival was 96% at 2 and 5 years, There was one death from Hodgkin's disease and one death from an M5 acute leukemia. Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantation, The freedom from second progression for the seven relapsed patients was estimated at 98% at 3 years,Conclusion: Stanford V chemotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin's disease in a multiinstitutional setting, On this basis, on Intergroup study comparing doxorubicin, bleomycin, vinblastine, and dacarbazine with the Stanford V regimen has been initiated. J Clin Oncol 18:972-980, (C) 2000 by American Society of Clinical Oncology.